Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes.
ADME
DMET Plus
SNP
hematological malignancies
multiple myeloma
risk alleles
single nucleotide polymorphism
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
06 01 2022
06 01 2022
Historique:
received:
13
11
2021
revised:
27
12
2021
accepted:
04
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
23
2
2022
Statut:
epublish
Résumé
The cause of multiple myeloma (MM) remains largely unknown. Several pieces of evidence support the involvement of genetic and multiple environmental factors (i.e., chemical agents) in MM onset. The inter-individual variability in the bioactivation, detoxification, and clearance of chemical carcinogens such as asbestos, benzene, and pesticides might increase the MM risk. This inter-individual variability can be explained by the presence of polymorphic variants in absorption, distribution, metabolism, and excretion (ADME) genes. Despite the high relevance of this issue, few studies have focused on the inter-individual variability in ADME genes in MM risk. To identify new MM susceptibility loci, we performed an extended candidate gene approach by comparing high-throughput genotyping data of 1936 markers in 231 ADME genes on 64 MM patients and 59 controls from the CEU population. Differences in genotype and allele frequencies were validated using an internal control group of 35 non-cancer samples from the same geographic area as the patient group. We detected an association between MM risk and
Identifiants
pubmed: 35053305
pii: cells11020189
doi: 10.3390/cells11020189
pmc: PMC8773885
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Chemother Pharmacol. 2016 Jan;77(1):205-9
pubmed: 26607259
Leukemia. 2020 Mar;34(3):697-708
pubmed: 31913320
Br J Haematol. 2011 Aug;154(4):529-33
pubmed: 21517810
Oncotarget. 2016 Dec 27;7(52):85895-85904
pubmed: 27825144
Biosci Rep. 2019 Apr 2;39(4):
pubmed: 30872408
BMC Bioinformatics. 2012 Oct 05;13:258
pubmed: 23035929
Curr Cancer Drug Targets. 2012 Sep;12(7):757-67
pubmed: 22671925
Leukemia. 2012 Jun;26(6):1419-22
pubmed: 22182917
Pharmacogenomics. 2015 Dec;16(18):2055-67
pubmed: 26616152
Bioinformatics. 2020 Aug 1;36(15):4377-4378
pubmed: 32437515
Clin Pharmacol Ther. 2019 Aug;106(2):422-431
pubmed: 30739312
Clin Transl Sci. 2021 Jan;14(1):113-119
pubmed: 33089968
Blood. 2009 Jun 18;113(25):6386-91
pubmed: 19387005
Cancers (Basel). 2020 Nov 13;12(11):
pubmed: 33202946
Nat Commun. 2019 Sep 19;10(1):4274
pubmed: 31537791
High Throughput. 2018 Oct 26;7(4):
pubmed: 30373182
Oncotarget. 2017 Nov 18;8(64):107558-107564
pubmed: 29296186
BMC Bioinformatics. 2021 Sep 30;22(Suppl 13):376
pubmed: 34592927
Blood. 2007 Apr 15;109(8):3177-88
pubmed: 17185464
Nat Commun. 2018 Sep 13;9(1):3707
pubmed: 30213928
Cancer Chemother Pharmacol. 2013 Sep;72(3):669-82
pubmed: 23934321
Front Oncol. 2019 Oct 11;9:1056
pubmed: 31681592
BMC Cancer. 2020 Nov 4;20(1):1062
pubmed: 33148208